Trial Profile
A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Pemetrexed (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 29 Nov 2007 The expected completion date for this trial is now 1 Oct 2007.
- 29 Nov 2007 Status changed from in progress to completed according to ClinicalTrials.gov.
- 28 Jul 2006 Status change